20 Jaar Interuniversitair Centrum voor Onderwijsonderzoek: een retrospectief

Het Interuniversitair Centrum voor Onderwijsonderzoek (ICO) bestaat meer dan 20 jaar. Dit artikel blikt terug op de ontwikkeling van de school en onderzoekt of de doelstellingen bereikt zijn: (1) het bevorderen van de kwaliteit van het wetenschappelijk onderwijs voor promovendi; (2) het bevorderen van de kwaliteit van het onderwijskundige onderzoek, en (3) het bevorderen van samenwerking. Vervolgens wordt de groei en bloei van ICO besproken aan de hand van een onderzoek, waarbij voor elk van de drie doelen is nagegaan hoe ICO zich over een periode van twee decennia ontwikkeld heeft. Ook wordt stilgestaan bij de korte periode (2004-2005) dat ICO niet erkend werd door de KNAW. De terugblik eindigt met de bespreking van toekomstgerichte ontwikkelingen binnen ICO. De belangrijkste conclusie is dat ICO zijn doelen bereikt heeft. In de toekomst zal internationale samenwerking belangrijker worden en het accent minder op kwaliteitsbewaking van onderzoek en meer op het verzorgen van hoogwaardig onderwijs voor promovendi komen te liggen

Author Correction: A consensus-based transparency checklist.

An amendment to this paper has been published and can be accessed via a link at the top of the paper

A consensus-based transparency checklist

We present a consensus-based checklist to improve and document the transparency of research reports in social and behavioural research. An accompanying online application allows users to complete the form and generate a report that they can submit with their manuscript or post to a public repository

Efficacy of halopeRIdol to decrease the burden of Delirium In adult Critically ill patiEnts (EuRIDICE): study protocol for a prospective randomised multi-centre double-blind placebo-controlled clinical trial in the Netherlands

Introduction Delirium in critically ill adults is associated with prolonged hospital stay, increased mortality and greater cognitive and functional decline. Current practice guideline recommendations advocate the use of nonpharmacological strategies to reduce delirium. The routine use of scheduled haloperidol to treat delirium is not recommended given a lack of evidence regarding its ability to resolve delirium nor improve relevant short-term and longer-term outcomes. This study aims to evaluate the efficacy and safety of haloperidol for the treatment of delirium in adult critically ill patients to reduce days spent with coma or delirium. Methods and analysis EuRIDICE is a prospective, multicentre, randomised, double-blind, placebo-controlled trial. Study population consists of adult intensive care unit (ICU) patients without acute neurological injury who have delirium based on a positive Intensive Care Delirium Screening Checklist (ICDSC) or Confusion Assessment Method for the ICU (CAM-ICU) assessment. Intervention is intravenous haloperidol 2.5mg (or matching placebo) every 8 hours, titrated daily based on ICDSC or CAMICU positivity to a maximum of 5mg every 8 hours, until delirium resolution or ICU discharge. Main study endpoint is delirium and coma-free days (DCFD) up to 14 days after randomisation. Secondary endpoints include (1) 28-day and 1-year mortality, (2) cognitive and functional performance at 3 and 12 months, (3) patient and family delirium and ICU experience, (4) psychological sequelae during and after ICU stay, (4) safety concerns associated with haloperidol use and (5) cost-effectiveness. Differences in DCFDs between haloperidol and placebo group will be analysed using Poisson regression analysis. Study recruitment started in February 2018 and continues. Ethics and dissemination The study has been approved by the Medical Ethics Committee of the Erasmus University Medical Centre Rotterdam (MEC2017-511) and by the Institutional Review Boards of the participating sites. Its results will be disseminated via peer-reviewed publication and conference presentations